骨关节炎的个体化医学：我们现在在哪里？
Personalized medicine for osteoarthritis: where are we now?
机构信息
Internal Medicines, University of Utah, 30N 1900E SOM, 4B200, Salt Lake City, UT 84132, USA.
出版信息
Ther Adv Musculoskelet Dis. 2013 Apr;5(2):67-75. doi: 10.1177/1759720X12470752.
Personalized medicine is a much talked about subject that is a timely and important development to healthcare in general and also specifically for patients affected by osteoarthritis. This review uses biomarker examples pertinent to osteoarthritis to highlight the current status of the field, while also highlighting probable future developments. It is not meant to be an exhaustive account. The BIPED(s) [Burden of disease, Investigative, Prognosis, Efficacy, Diagnosis (safety)] classification system is used to organize the discussion of examples. Biomarkers pertaining to burden, investigation, prognosis, efficacy, diagnosis and safety are highlighted. The examples are followed by a discussion of issues related to interpretation and application of biomarker results and approaches to solve the challenges interpretation faces, including graphical, mathematical and synthetic representations. Through this review, it is hoped that a better appreciation can be gained of the potential and pitfalls of personal medicine in the care of patients with osteoarthritis.
个体化医学是一个备受关注的话题，它是医疗保健领域的一项及时而重要的发展，特别是对患有骨关节炎的患者而言。本文使用与骨关节炎相关的生物标志物示例来突出该领域的现状，同时也强调可能的未来发展。这并不是一个详尽的描述。BIPED（疾病负担、调查、预后、疗效、诊断（安全性））分类系统用于组织对示例的讨论。突出了与疾病负担、调查、预后、疗效、诊断和安全性相关的生物标志物。在示例之后，讨论了与生物标志物结果的解释和应用相关的问题，以及解决解释所面临挑战的方法，包括图形、数学和综合表示。通过这篇综述，希望能够更好地了解个体化医学在骨关节炎患者护理中的潜力和陷阱。
Zotero 插件